Victoria M Ettorre

6PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 14, 2026
A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.

|Sep 27, 2025
Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor.

Cem Demirkiran, Stefania Bellone, Victoria M Ettorre

|Aug 27, 2025
HER2/neu as a Signaling and Therapeutic Marker in Uterine Serous Carcinoma.

Victoria M Ettorre, Luca Palmieri, Valentino Clemente

|Aug 27, 2025
Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas.

Niccolò G Santin, Namrata Sethi, Stefania Bellone

|Jun 13, 2025
Personalized Treatment in Ovarian Cancer: A Review of Disease Monitoring, Biomarker Expression, and Targeted Treatments for Advanced, Recurrent Ovarian Cancers.

Victoria M Ettorre, Abdelrahman AlAshqar, Namrata Sethi

|Apr 29, 2025
Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.

Michelle Greenman, Cem Demirkiran, Stefania Bellone

Pageof 1

Frequent Collaborators

6 joint publications

Alessandro D Santin

4 joint publications

Namrata Sethi

4 joint publications

Blair McNamara

4 joint publications

Stefania Bellone